Home/Filings/4/0001209191-20-061537
4//SEC Filing

Primiano Christopher Brett 4

Accession 0001209191-20-061537

CIK 0001503802other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 5:17 PM ET

Size

14.4 KB

Accession

0001209191-20-061537

Insider Transaction Report

Form 4
Period: 2020-12-01
Primiano Christopher Brett
VP, Gen Counsel & Secretary
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-12-0158,93716,842 total
    Exercise: $10.39Exp: 2027-01-19Common Stock (58,937 underlying)
  • Sale

    Common Stock

    2020-12-01$17.66/sh78,124$1,379,6704,523 total
  • Exercise/Conversion

    Common Stock

    2020-12-01$10.39/sh+58,937$612,35563,460 total
  • Sale

    Common Stock

    2020-12-01$17.35/sh58,937$1,022,5574,523 total
  • Exercise/Conversion

    Common Stock

    2020-12-01$10.45/sh+78,124$816,39682,647 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-12-0178,12446,876 total
    Exercise: $10.45Exp: 2028-01-23Common Stock (78,124 underlying)
Footnotes (3)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
  • [F3]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001603510

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 5:17 PM ET
Size
14.4 KB